PD-1 Inhibitor + Chemotherapy

DRUG2 trials

Sponsors

West China Hospital, Shenyang Sunshine Pharmaceutical Co., LTD.

Conditions

First-line Advanced NSCLC PatientsTNBC - Triple-Negative Breast Cancer

Phase 2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

RecruitingNCT07171606

Shenyang Sunshine Pharmaceutical Co., LTD.First-line Advanced NSCLC Patients

Start: 2025-10-24End: 2027-08-31Target: 240Updated: 2025-12-18

Phase 3

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

RecruitingNCT06627712

West China HospitalTNBC - Triple-Negative Breast Cancer

Start: 2024-11-01End: 2031-11-01Target: 318Updated: 2026-01-30